Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET

Company Participants

Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs
Mina Kim - Chief Executive Officer
Shep Mpofu - Chief Medical Officer
Gil Labrucherie - Chief Financial Officer and Chief Business Officer

Conference Call Participants

Derek Archila - Wells Fargo
Tyler Van Buren - TD Cowen
Yasmeen Rahimi - Piper Sandler
Phoebe Tan - Jefferies
Emily Bodnar - H.C. Wainwright
Vikram Purohit - Morgan Stanley
Samantha Semenkow - Citi

Operator

Good afternoon, and welcome to the ACELYRIN INC. Conference Call to discuss the company's second quarter 2024 financial results and other corporate updates. This conference call is being recorded today, August 13, 2024.

I would now like to turn the conference call over to Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs. Tyler?

Tyler Marciniak

Thank you, Carmen. Good afternoon, everyone, and thank you for joining us. Before we begin, I'd like to remind you that this conference call may contain forward-looking statements such as those related to progress of our clinical trials and anticipated data readouts, our future financial and operating results and projected cash runway, and our ability to commercialize our product candidates. These forward-looking statements involve risks and uncertainties that could cause our actual results and events to differ materially.

We would urge you to review the Risk Factors section of our Form 10-Q for the quarter ended June 30, 2024, and additional Form 8-K that we filed with the SEC, both of which are also available on our website at acelyrin.com along with today's press release and our slide presentation. Additionally, these statements are based on information available to us today, August 13, 2024, and we undertake no obligation to update them as circumstances may change.

The agenda for today's call is on the screen. We will review the corporate strategy updates announced in our press release, as well as positive top-line data from the Phase 3 trial of izokibep in hidradenitis suppurativa. We will also provide an update on the lonigutamab program in TED and close with a financial update highlighting our projected three-year cash runway covering multiple anticipated milestones.

Joining us on today's call are Mina Kim, our Chief Executive Officer; Dr. Shep Mpofu, our Chief Medical Officer; and Gil Labrucherie, our Chief Financial Officer and Chief Business Officer.

I will now turn the call over to Mina.